Results 151 to 160 of about 29,210 (297)

Ibrutinib-Induced Skin Rash

open access: yesTurkish Journal of Hematology, 2021
Sudhir Kirar   +3 more
openaire   +2 more sources

Targeting the Ubiquitin–Proteasome System for Cancer

open access: yesMedComm, Volume 6, Issue 10, October 2025.
This figure shows the mechanism of protein degradation by ubiquitin–proteasome system. The process begins with ubiquitin activation by the E1 enzyme, forming a thioester bond between E1's cysteine residue and ubiquitin's glycine carboxyl group, powered by ATP hydrolysis.
Zhaoyun Liu   +5 more
wiley   +1 more source

The Impact of Tirabrutinib Monotherapy for the Treatment of Bing‐Neel Syndrome: A Multicenter Retrospective Study

open access: yes
American Journal of Hematology, Volume 100, Issue 10, Page 1912-1915, October 2025.
Masuho Saburi   +19 more
wiley   +1 more source

Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

open access: bronze, 2013
Betty Chang   +14 more
openalex   +1 more source

Chemical Engineering of Heterojunction SERS Substrates: Emerging Tools for Disease Diagnosis and Health Monitoring

open access: yesSmartMat, Volume 6, Issue 5, October 2025.
This review summarizes the design, preparation and application of heterojunction SERS substrates, covering various aspects such as environmental monitoring, food safety, and biosensing. It holds significant guiding significance for the development of new SERS substrates and also presents the challenges and future directions of SERS technology ...
Mingjian Zhang   +10 more
wiley   +1 more source

Secondary central nervous system lymphoma (SCNSL) in mantle cell lymphoma (MCL): Characteristics and risk factors in a Danish nationwide population‐based study

open access: yesBritish Journal of Haematology, Volume 207, Issue 4, Page 1366-1376, October 2025.
In a nationwide cohort study, 873 patients with mantle cell lymphoma (MCL) were followed for a median of 7 years. During follow‐up, 28 patients developed secondary central nervous system (CNS) lymphoma (SCNSL) with a 5‐year cumulative incidence of 2.8% (95% confidence interval [CI] 1.7–3.9).
Trine Trab   +15 more
wiley   +1 more source

Predictive Analysis for First Submission of Generic Drug Application for Orphan Drug Products Using Random Survival Forest

open access: yesClinical and Translational Science, Volume 18, Issue 10, October 2025.
ABSTRACT Rare diseases affect a small population of patients, resulting in low incentives for developing orphan drug products (ODPs). The United States Congress passed the Orphan Drug Act of 1983 to incentivize pharmaceutical manufacturers to develop drugs to treat rare diseases.
Robert Hopefl   +6 more
wiley   +1 more source

Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib

open access: bronze, 2014
Dominik Wodarz   +9 more
openalex   +1 more source

Ibrutinib And Oral Ulcers [PDF]

open access: yesClinical Dermatology & Therapy, 2020
openaire   +1 more source

Comparative analysis of macrophage feeder systems reveals distinct behaviors and key transcriptional shifts in chronic lymphocytic leukemia cells via coculture

open access: yes
HemaSphere, Volume 9, Issue 10, October 2025.
Viktoria Kohlhas   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy